BioinvestGPT

BioinvestGPT ApS · Research use only

NCT05352893 (Imsidolimab in Generalized Pustular Psoriasis): BVCT ex-ante prediction vs. reported outcome

On 27 Dec 2022, BioinvestGPT's BVCT predicted technical success and commercial success for this trial. The 9 May 2024 readout is classified on the dashboard as True Positive (TP), a correct prediction. Recorded clinical-benefit conclusion: statistically significant and commercially sufficient.

Clinical Trial

NCTID
NCT05352893
Acronym
GEMINI-1
Drug Name
Imsidolimab (ANB019)
Drug MoA
anti-IL36R mAb inhibitor
Drug Modality
monoclonal antibody (mAb)
Drug Class
First-In-Class
Therapeutic Area
Immune System Diseases
Indication
Generalized Pustular Psoriasis
Human Patients
45
Sponsor
AnaptysBio
Phase
Phase 3

Prediction of , index 822

Prospective Prediction
Prediction Index
822
Prediction Date
Commercial Prediction
SUCCESS
Technical Prediction
SUCCESS

Readout of

Prediction Validation
Readout Date
Prediction To Readout
499 days in advance
Readout Data Interpretation
40% placebo-adjusted GPPPGA score 0/1 (p=0.0131) in GEMINI1.
Press Release
Prediction Result
Prediction Accuracy
Correct Prediction
Clinical Benefit Conclusion
statistically significant and commercially sufficient
Prediction Classification
True Positive (TP)

ClinicalTrials.gov record

ClinicalTrials.gov record, retrieved 2026-09-24. Third-party data.

Official title
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Imsidolimab (ANB019) in the Treatment of Adult Subjects With Generalized Pustular Psoriasis
Phase
Phase 3
Status
Completed
Enrollment
45
Lead sponsor
Vanda Pharmaceuticals
Conditions
Generalized Pustular Psoriasis
Interventions
DRUG: 750 mg Imsidolimab; DRUG: 300 mg Imsidolimab; OTHER: Placebo
Design
Randomized · Parallel · Quadruple
Primary purpose
Treatment
Start
2022-04-14
Primary completion
2023-08-17
Completion
2023-08-17
Results first posted
2026-03-17
Primary outcomes
  • Percentage of Patients Achieving a GPPPGA Score of 0 (Clear) or 1 (Almost Clear) (Week 4)

NCT05352893 on ClinicalTrials.gov

Return to the dashboardClinicalTrials.gov

How to read these records: evidence · methodology · all trials